Zobrazeno 1 - 10
of 48
pro vyhledávání: '"JA Garcia-Saenz"'
Autor:
Gonzalo Gómez-López, J. Cortés, Luis Manso, Ivana Zagorac, C Fustero, S Mouron, A. Lluch, P Tapial-Martinez, J Muñoz, Lucía González-Cortijo, Isabel Calvo, Miguel Quintela-Fandino, JA Garcia-Saenz
Publikováno v:
Cancer Research. 79:PD2-09
Background: NGS has elucidated the mutational landscape in BC. However, the correlation between mutational landscapes and complex phenotypic traits such as drug response is yet unclear. The genomic and transcriptomic aberrations coalesce into a diver
Autor:
Matthias Schwenkglenks, Nicole McCarthy, Harry D. Bear, Andreas Makris, Nicole Burchardi, M. Toi, P. Salari, Michael Untch, M. Martin, F Marmé, T. Reimer, HS Rugo, JA Garcia-Saenz, S. Loibl, Catherine M. Kelly, K. Galactionova, M. Gnant, Karen A. Gelmon, S-B Kim, Hervé Bonnefoi
Publikováno v:
Annals of Oncology. 32:S416-S417
Autor:
Adela Castelló, A. De Juan, JA Garcia-Saenz, M. Ramos, A. Lluch, Antonio Antón, P. Sanchez Rovira, Beatriz Pérez-Gómez, Jose Ignacio Chacon, Eva Carrasco, Montse Muñoz, Marina Pollán, Virginia Lope, Silvia Antolín, J. M. Baena, Carlos Poblete Jara, A. Ruiz, Susana Bezares, A. Arcusa, M. Martin, M. A. Jimeno, Ana M. Casas
Publikováno v:
Cancer Research. 78:P3-09
Introduction: It has been reported that overeating may be the greatest avoidable cause of cancer in nonsmokers and obesity increases postmenopausal breast cancer (BC) risk. Calorie restriction reduces BC incidence in experimental animals, but the evi
Autor:
V Ruiz, J Hoffman, F Moreno-Antón, Rosalia Caballero, JA Garcia-Saenz, B. Adamo, Lourdes Calvo, D Wang, Silvia Antolín, Eva Carrasco, Alvaro Montaño, Miguel Gil-Gil, Catalina Falo, P Crownover, M. Martin, Manuel Ruiz-Borrego, Christiane Thallinger, Nuria Martin, Agostina Stradella, Montse Muñoz, E. Alba
Publikováno v:
Cancer Research. 78:P5-21
Background: Palbociclib (PAL) is an oral cyclin-dependent kinase (CDK) 4/6 inhibitor that is under investigation in multiple oncologic clinical trials and is currently approved for use in combination with aromatase inhibitors (AIs) or fulvestrant (FU
Autor:
Roberto Torres, P López-Álvarez, Carlos Sampaio, Carlos Barrios, E Villar, Eva Carrasco, A. Lluch, L Pérez-Michel, J.G.M. Segalla, S. Reyes, JA Garcia-Saenz, J. Cárdenas, Maria Jose Godes, M. Ramos, J Castellanos, A. Ruiz, M. J. Escudero, E Martínez de Dueñas, Lourdes Calvo, J Moncayo, J. M. Baena, Manuel Ruiz-Borrego, J. Vinholes, L Torrecillas, Susana Bezares, M. Martin, Henry L. Gomez, Agust Barnadas, M. A. Seguí, Antonio Llombart, Gilberto Luiz da Silva Amorim, J. Bines, Álvaro Rodríguez-Lescure, M Rodríguez de la Borbolla, Antonio Antón, J de la Haba, B Cardemil, E Garcia
Publikováno v:
Cancer Research. 79:GS2-04
Background: Triple negative breast cancers (TNBC) have a greater risk of relapse than non-TNBC. New therapeutic approaches are needed for these patients (pts). CIBOMA/2004-01_GEICAM/2003-11 is a multinational, randomized phase III trial exploring adj
Autor:
Pilar Sánchez, Isabel Ruiz, Jose Perez-Garcia, Marcos Vinicius Silva Oliveira, Antonio Llombart-Cussac, Juan Antonio Virizuela, JC Quero Guillen, Santiago González-Santiago, K Zaragoza, Antonia Perelló, L de la Pena, JA Garcia-Saenz, Joaquín Gavilá, Antonio González-Martín, B Cantos Sánchez de Ibargüen, Serafin Morales, Montse Muñoz, I. Garau Llinas, Inmaculada Calvo, Eva Ciruelos, Raquel Andrés
Publikováno v:
Cancer Research. 77:P4-21
INTRODUCTION Targeting HER2 by dual blockade with trastuzumab (T) and pertuzumab (P) in a taxane-based regimen is an active neoadjuvant treatment (NAT) of HER2+ early breast cancer (EBC). Addition of an anthracycline could further enhance this respon
Autor:
Pierre Squifflet, S Sleijfers, D Peeters, Jorge S. Reis-Filho, A Fernandez de Lascoiti, Camillo Almici, Salvatore Grisanti, Daniele Generali, Nick Beije, Cristina Raimondi, L. De Mattos-Arruda, Carlos Caldas, J-Y Pierga, L.Y. Dirix, D. Mavroudis, Alberto Bottini, Pier Paolo Gazzaniga, Wolfgang Janni, F-C Bidard, Stefan Michiels, Jonathan Krell, Jose Vidal-Martinez, Rita Zamarchi, S-J Dawson, Laura Zorzino, Annemie Rutten, Franco Nolè, Sophia Agelaki, Francesca Consoli, JA Garcia-Saenz, Michail Ignatiadis, S. Van Laere, Elisabetta Munzone, Rafael Gisbert-Criado, E Solomayer, Eleni Politaki, M. T. Sandri, Eduardo Díaz-Rubio, Luis Manso, Justin Stebbing, Klaus Pantel, Tanja Fehm, Vicente Carañana, Franziska Meier-Stiegen
Publikováno v:
Cancer Research. 76:P2-08
Background: The European Pooled Analysis of CTC (EPAC) in metastatic breast cancer, based on 1,944 individual data from patients with various tumor types and clinical settings (Bidard et al, Lancet Oncol 2014), has established CTC count (CellSearch)
Autor:
Josefina Cruz, Noelia Martínez-Jañez, Serafin Morales, M. Martin, J. de la Haba-Rodríguez, Ángel L Guerrero, Federico Rojo, C Rodríguez-Martin, Mireia Margeli, Patricia Galván, Rosalia Caballero, Pedro Sánchez-Rovira, JA Garcia-Saenz, Antonio Antón, Sonia González, Eva Carrasco, Aleix Prat, Antonia Perelló, Sonia Servitja, M Casas, Montse Muñoz, Manuel Ramos
Publikováno v:
Cancer Research. 76:P3-07
Introduction: The role of bevacizumab in combination with chemotherapy in metastatic BC is controversial, and no biomarker exists as of today that predicts benefit to this agent. In the LEA clinical trial, a numerical, statistically non-significant b
Autor:
A González-Farré, LA Fernández-Morales, E Damau, Laura Murillo, Antonio Llombart, Lourdes Calvo, Carlos Poblete Jara, Manuel Ramos, Serafin Morales, AI García, MdM Angulo, Maribel Casas, Vicente Carañana, JA Garcia-Saenz, Eva Carrasco, Xavier Gonzalez, MC Cámara
Publikováno v:
Cancer Research. 73:P3-15
Background: Docetaxel-Cyclophosphamide (TC) has become a common chemotherapy regimen for moderate-high risk Early Breast Cancer (EBC) patients. The incidence of chemotherapy induced nausea and vomiting (CINV) with TC together with an adequate standar
Autor:
Antonio Antón, Cornelia Liedtke, G. von Minckwitz, Grischa Wachsmann, J de la Haba, Montse Muñoz, Gbg, Miquel Gil, M. Martin, Manuel Ramos, Eva Carrasco, Winfried Schoenegg, C. Crespo, JA Garcia-Saenz, Bahriye Aktas, Keyur Mehta, Ángel L Guerrero, Serafin Morales, S. Loibl
Publikováno v:
Cancer Research. 72:S1-7
Background: Preclinical data (de la Haba J, AACR 2011) and retrospective clinical data (Mander P, Cancer 2003; Linderhol B, JCO 2000) suggest that high vascular endothelial growth factor (VEGF) levels in breast tumors are associated with a decreased